Patents by Inventor Takuto Kojima
Takuto Kojima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230037538Abstract: The present invention relates to compounds expected to be useful in the prevention and/or treatment of diseases such as amyotrophic lateral sclerosis, frontotemporal dementia, chronic traumatic encephalopathy, Alzheimer's disease, frontotemporal lobar degeneration, multisystem proteinopathy and the like, a method for preventing or treating such diseases, and the like.Type: ApplicationFiled: June 23, 2022Publication date: February 9, 2023Inventors: Dennis Solas, Anatoliy Kitaygorodskyy, Kumar Paulvannan, Vishwanath R. Lingappa, Masato Yoshikawa, Masahiro Ito, Yuta Tanaka, Keiko Kakegawa, Tomohiro Ohashi, Takuto Kojima, Akinori Toita, Osamu Kubo, Fumiaki Kikuchi, Florian Pünner, Junsi Wang
-
Publication number: 20220370491Abstract: The object of the present invention is to provide a nucleic acid agent that is efficiently delivered to the nervous system, for example, the central nervous system to which drug delivery can be prevented by BBB, and produces an antisense effect on the target transcriptional product at the delivery site, and a composition comprising the same. In an embodiment, the present invention provides a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand that hybridizes to a part of a target transcriptional product and has an antisense effect on the target transcriptional product, and a second nucleic acid strand that comprises a base sequence complementary to the first nucleic acid strand and is bound to a C22-35 alkyl group optionally substituted with a hydroxy group or an analog thereof.Type: ApplicationFiled: September 16, 2020Publication date: November 24, 2022Applicants: National University Corporation Tokyo Medical and Dental University, Takeda Pharmaceutical Company LimitedInventors: Takanori Yokota, Testuya Nagata, Hideki Furukawa, Takatoshi Yogo, Yasuo Nakagawa, Shigekazu Sasaki, Ryosuke Tokunoh, Tomohiro Seki, Kosuke Hidaka, Fumiaki Kikuchi, Osamu Kubo, Takahito Kasahara, Takuto Kojima, Junsi Wang, Norihito Tokunaga
-
Patent number: 11390634Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].Type: GrantFiled: December 22, 2020Date of Patent: July 19, 2022Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Youichi Kawakita, Takuto Kojima, Noriyuki Nii, Yoshiteru Ito, Nobuki Sakauchi, Hiroshi Banno, Xin Liu, Koji Ono, Keisuke Imamura, Shinichi Imamura
-
Publication number: 20220098180Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: ApplicationFiled: January 29, 2020Publication date: March 31, 2022Applicant: Takeda Pharmaceutical Company LimitedInventors: Masahiro ITO, Takeshi YAMAMOTO, Keiko KAKEGAWA, Hideyuki SUGIYAMA, Tohru MIYAZAKI, Yasuyoshi ARIKAWA, Tomohiro OKAWA, Jinichi YONEMORI, Osamu KUBO, Akinori TOITA, Takuto KOJIMA, Fumiaki KIKUCHI, Minoru SASAKI, Misaki HOMMA, Yasuhiro IMAEDA, Hironobu MAEZAKI, Shiinobu SASAKI, Ayumu SATO, Hirotaka KAMITANI, Yasutomi ASANO, Hironori KOKUBO, Masato YOSHIKAWA
-
Publication number: 20210179603Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.Type: ApplicationFiled: February 16, 2021Publication date: June 17, 2021Inventors: Shigemitsu MATSUMOTO, Yasushi HATTORI, Masashi TOYOFUKU, Shinji MORIMOTO, Masaki DAINI, Takuto KOJIMA, Tomohiro KAKU, Mitsuhiro ITO
-
Publication number: 20210115067Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].Type: ApplicationFiled: December 22, 2020Publication date: April 22, 2021Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Youichi KAWAKITA, Takuto KOJIMA, Noriyuki NII, Yoshiteru ITO, Nobuki SAKAUCHI, Hiroshi BANNO, Xin LIU, Koji ONO, Keisuke IMAMURA, Shinichi IMAMURA
-
Patent number: 10981934Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].Type: GrantFiled: October 25, 2019Date of Patent: April 20, 2021Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Youichi Kawakita, Takuto Kojima, Noriyuki Nii, Yoshiteru Ito, Nobuki Sakauchi, Hiroshi Banno, Xin Liu, Koji Ono, Keisuke Imamura, Shinichi Imamura
-
Patent number: 10968213Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.Type: GrantFiled: June 27, 2019Date of Patent: April 6, 2021Assignee: Takeda Pharmaceutical Company LimitedInventors: Shigemitsu Matsumoto, Yasushi Hattori, Masashi Toyofuku, Shinji Morimoto, Masaki Daini, Takuto Kojima, Tomohiro Kaku, Mitsuhiro Ito
-
Patent number: 10899752Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: GrantFiled: April 25, 2019Date of Patent: January 26, 2021Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
-
Patent number: 10696651Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: GrantFiled: August 9, 2017Date of Patent: June 30, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Jun Fujimoto, Xin Liu, Osamu Kurasawa, Terufumi Takagi, Douglas Robert Cary, Hiroshi Banno, Yasutomi Asano, Takuto Kojima
-
Patent number: 10676461Abstract: The present invention relates to N-((3S,4R)-1-((8-chloroquinoxalin-6-yl)carbonyl)-3-(4-fluorophenyl)piperidin-4-yl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide, which is a compound that can be useful for the treatment or prevention of SPT-related diseases including congenital diseases associated with the storage of sphingolipids, such as cancer and Niemann-Pick disease, or a salt thereof.Type: GrantFiled: October 17, 2017Date of Patent: June 9, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Katsunori Nagai, Takuto Kojima, Shinichi Imamura, Masao Hirakata
-
Publication number: 20200140462Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].Type: ApplicationFiled: October 25, 2019Publication date: May 7, 2020Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Youichi KAWAKITA, Takuto KOJIMA, Noriyuki NII, Yoshiteru ITO, Nobuki SAKAUCHI, Hiroshi BANNO, Xin LIU, Koji ONO, Keisuke IMAMURA, Shinichi IMAMURA
-
Patent number: 10577382Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein].Type: GrantFiled: April 27, 2017Date of Patent: March 3, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Youichi Kawakita, Takuto Kojima, Noriyuki Nii, Yoshiteru Ito, Nobuki Sakauchi, Hiroshi Banno, Xin Liu, Koji Ono, Keisuke Imamura, Shinichi Imamura
-
Patent number: 10548899Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.Type: GrantFiled: October 19, 2016Date of Patent: February 4, 2020Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masaki Ogino, Eiji Kimura, Masataka Murakami, Takuto Kojima, Jinichi Yonemori
-
Patent number: 10519110Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).Type: GrantFiled: October 30, 2018Date of Patent: December 31, 2019Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yasutomi Asano, Takuto Kojima, Osamu Kurasawa, Tzu-Tshin Wong, Yasuhiro Hirata, Naoki Iwamura, Bunnai Saito, Yuta Tanaka, Ryosuke Arai, Shinichi Imamura, Kazuko Yonemori, Yasufumi Miyamoto, Shuji Kitamura, Osamu Sano
-
Publication number: 20190315735Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.Type: ApplicationFiled: June 27, 2019Publication date: October 17, 2019Inventors: Shigemitsu MATSUMOTO, Yasushi HATTORI, Masashi TOYOFUKU, Shinji MORIMOTO, Masaki DAINI, Takuto KOJIMA, Tomohiro KAKU, Mitsuhiro ITO
-
Patent number: 10435399Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: July 30, 2018Date of Patent: October 8, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Masahiro Ito, Hideyuki Sugiyama, Osamu Kubo, Fumiaki Kikuchi, Takeshi Yasui, Keiko Kakegawa, Zenichi Ikeda, Tohru Miyazaki, Yasuyoshi Arikawa, Tomohiro Okawa, Jinichi Yonemori, Akinori Toita, Takuto Kojima, Yasutomi Asano, Ayumu Sato, Hironobu Maezaki, Shinobu Sasaki, Hironori Kokubo, Misaki Homma, Minoru Sasaki, Yasuhiro Imaeda
-
Patent number: 10428056Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: GrantFiled: August 27, 2018Date of Patent: October 1, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
-
Patent number: 10414761Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.Type: GrantFiled: January 29, 2018Date of Patent: September 17, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Shigemitsu Matsumoto, Yasushi Hattori, Masashi Toyofuku, Shinji Morimoto, Masaki Daini, Takuto Kojima, Tomohiro Kaku, Mitsuhiro Ito
-
Publication number: 20190263784Abstract: The present invention relates to N-((3S,4R)-1-((8-chloroquinoxalin-6-yl)carbonyl)-3-(4-fluorophenyl)piperidin-4-yl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide, which is a compound that can be useful for the treatment or prevention of SPT-related diseases including congenital diseases associated with the storage of sphingolipids, such as cancer and Niemann-Pick disease, or a salt thereof.Type: ApplicationFiled: October 17, 2017Publication date: August 29, 2019Inventors: Katsunori NAGAI, Takuto KOJIMA, Shinichi IMAMURA, Masao HIRAKATA